DK2976359T4 - Fremgangsmåder til behandling af osteogenesis imperfecta - Google Patents
Fremgangsmåder til behandling af osteogenesis imperfecta Download PDFInfo
- Publication number
- DK2976359T4 DK2976359T4 DK14717386.8T DK14717386T DK2976359T4 DK 2976359 T4 DK2976359 T4 DK 2976359T4 DK 14717386 T DK14717386 T DK 14717386T DK 2976359 T4 DK2976359 T4 DK 2976359T4
- Authority
- DK
- Denmark
- Prior art keywords
- procedures
- treatment
- osteogenesis imperfecta
- imperfecta
- osteogenesis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361803647P | 2013-03-20 | 2013-03-20 | |
| US201361875399P | 2013-09-09 | 2013-09-09 | |
| US201361883151P | 2013-09-26 | 2013-09-26 | |
| PCT/US2014/031279 WO2014153435A1 (en) | 2013-03-20 | 2014-03-20 | Methods for treating osteogenesis imperfecta |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK2976359T3 DK2976359T3 (da) | 2019-01-02 |
| DK2976359T4 true DK2976359T4 (da) | 2022-06-13 |
Family
ID=50483613
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17206987.4T DK3312195T3 (da) | 2013-03-20 | 2014-03-20 | Fremgangsmåder til behandling af osteogenesis imperfecta |
| DK14717386.8T DK2976359T4 (da) | 2013-03-20 | 2014-03-20 | Fremgangsmåder til behandling af osteogenesis imperfecta |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17206987.4T DK3312195T3 (da) | 2013-03-20 | 2014-03-20 | Fremgangsmåder til behandling af osteogenesis imperfecta |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9598486B2 (da) |
| EP (3) | EP3312195B1 (da) |
| JP (3) | JP6483086B2 (da) |
| KR (1) | KR102257138B1 (da) |
| CN (2) | CN111000997A (da) |
| AU (1) | AU2014235933B2 (da) |
| CA (1) | CA2907422C (da) |
| CL (1) | CL2015002801A1 (da) |
| DK (2) | DK3312195T3 (da) |
| EA (1) | EA032327B1 (da) |
| ES (2) | ES2700238T5 (da) |
| HK (2) | HK1253717A1 (da) |
| HR (2) | HRP20181939T4 (da) |
| HU (1) | HUE046702T2 (da) |
| IL (2) | IL241461B (da) |
| LT (2) | LT2976359T (da) |
| MX (2) | MX369360B (da) |
| MY (1) | MY172324A (da) |
| PH (2) | PH12015501864B1 (da) |
| PL (2) | PL3312195T3 (da) |
| PT (2) | PT3312195T (da) |
| RS (2) | RS59673B1 (da) |
| SG (2) | SG11201506683XA (da) |
| SI (2) | SI2976359T2 (da) |
| TW (1) | TWI629995B (da) |
| UY (1) | UY35493A (da) |
| WO (1) | WO2014153435A1 (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2976359T2 (sl) * | 2013-03-20 | 2022-05-31 | Genzyme Corporation | Postopki zdravljenja imperfektne osteogeneze |
| WO2018027329A1 (en) * | 2016-08-11 | 2018-02-15 | Precithera, Inc. | TGF-β ANTAGONIST CONJUGATES |
| CN106755395B (zh) * | 2016-12-16 | 2020-05-12 | 山东第一医科大学(山东省医学科学院) | Xi型成骨不全致病基因fkbp10的突变位点及其应用 |
| TW202313678A (zh) * | 2017-01-20 | 2023-04-01 | 法商賽諾菲公司 | 抗TGF-β抗體及其用途 |
| EA201991729A1 (ru) * | 2017-01-20 | 2019-12-30 | Санофи | Антитела к tgf-бета и их применение |
| AR110904A1 (es) * | 2017-01-20 | 2019-05-15 | Sanofi Sa | ANTICUERPOS ANTI-TGF-b Y SU USO |
| AR110755A1 (es) * | 2017-01-20 | 2019-05-02 | Genzyme Corp | Anticuerpos dirigidos a hueso |
| US20190248881A1 (en) * | 2017-12-04 | 2019-08-15 | Precithera, Inc. | TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING |
| AU2019301283A1 (en) | 2018-07-10 | 2021-02-04 | Sanofi | Combination therapies against cancer targeting CD38 and TGF-beta |
| US20230391892A1 (en) * | 2020-10-23 | 2023-12-07 | Hq Han | Bifunctional antagonists of tumor necrosis factor alpha and transforming growth factor beta and uses thereof |
| KR20240018471A (ko) * | 2021-05-07 | 2024-02-13 | 베이롤 칼리지 오브 메드신 | 중등증 내지 중증 불완전 골형성증의 치료 |
| CN113501879B (zh) * | 2021-06-30 | 2022-09-06 | 拜盖特生物科技(上海)有限公司 | 一种解除肿瘤免疫微环境中免疫抑制的双功能抗体及其应用和制备方法 |
| CA3237245A1 (en) * | 2021-11-01 | 2023-05-04 | Genzyme Corporation | Treatment of osteogenesis imperfecta |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL6716836A (da) * | 1967-12-11 | 1969-06-13 | ||
| US7368111B2 (en) * | 1995-10-06 | 2008-05-06 | Cambridge Antibody Technology Limited | Human antibodies specific for TGFβ2 |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AU1525700A (en) * | 1998-11-19 | 2000-06-05 | Board Of Trustees Of The University Of Arkansas, The | Increasing bone strength with selected bisphosphonates |
| EP1133558B2 (en) * | 1998-11-27 | 2016-04-13 | UCB Pharma S.A. | Compositions and methods for increasing bone mineralization |
| US20040009535A1 (en) * | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| CA2308532C (en) * | 1999-05-12 | 2005-11-29 | Gador S.A. | Use of bisphosphonates for the treatment of osteogenesis imperfecta |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| PL3520815T3 (pl) | 2005-02-08 | 2022-04-11 | Genzyme Corporation | Przeciwciała przeciwko TGFBETA |
| TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| ATE545657T1 (de) * | 2005-12-23 | 2012-03-15 | Lilly Co Eli | Tgf-beta antikörper |
| WO2008022182A1 (en) * | 2006-08-16 | 2008-02-21 | The Uab Research Foundation | Methods for promoting coupling between bone formation and resorption |
| EA025371B1 (ru) * | 2007-02-09 | 2016-12-30 | Акселерон Фарма Инк. | АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ |
| JP2010528586A (ja) * | 2007-04-26 | 2010-08-26 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 骨形成及び鉱化作用を調節する化合物の同定のためのアッセイ |
| AR068767A1 (es) * | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
| ATE555131T1 (de) * | 2008-01-15 | 2012-05-15 | Kalobios Pharmaceuticals Inc | Verfahren zur behandlung von erkrankungen mit knochenabbau unter verwendung eines gm-csf- antagonisten |
| US20120294868A1 (en) * | 2009-04-24 | 2012-11-22 | Edwards James R | Anti-tgf-beta induction of bone cell function and bone growth |
| SI2976359T2 (sl) * | 2013-03-20 | 2022-05-31 | Genzyme Corporation | Postopki zdravljenja imperfektne osteogeneze |
-
2014
- 2014-03-20 SI SI201430985T patent/SI2976359T2/sl unknown
- 2014-03-20 JP JP2016504355A patent/JP6483086B2/ja active Active
- 2014-03-20 PL PL17206987T patent/PL3312195T3/pl unknown
- 2014-03-20 LT LTEP14717386.8T patent/LT2976359T/lt unknown
- 2014-03-20 EP EP17206987.4A patent/EP3312195B1/en active Active
- 2014-03-20 MX MX2015013402A patent/MX369360B/es active IP Right Grant
- 2014-03-20 SI SI201431435T patent/SI3312195T1/sl unknown
- 2014-03-20 US US14/772,708 patent/US9598486B2/en active Active
- 2014-03-20 SG SG11201506683XA patent/SG11201506683XA/en unknown
- 2014-03-20 MY MYPI2015702733A patent/MY172324A/en unknown
- 2014-03-20 CN CN201910988588.9A patent/CN111000997A/zh active Pending
- 2014-03-20 LT LTEP17206987.4T patent/LT3312195T/lt unknown
- 2014-03-20 ES ES14717386T patent/ES2700238T5/es active Active
- 2014-03-20 RS RS20191624A patent/RS59673B1/sr unknown
- 2014-03-20 EA EA201591843A patent/EA032327B1/ru not_active IP Right Cessation
- 2014-03-20 WO PCT/US2014/031279 patent/WO2014153435A1/en active Application Filing
- 2014-03-20 UY UY0001035493A patent/UY35493A/es not_active Application Discontinuation
- 2014-03-20 PL PL14717386.8T patent/PL2976359T5/pl unknown
- 2014-03-20 SG SG10201701985YA patent/SG10201701985YA/en unknown
- 2014-03-20 PT PT172069874T patent/PT3312195T/pt unknown
- 2014-03-20 EP EP14717386.8A patent/EP2976359B2/en active Active
- 2014-03-20 CN CN201480028990.8A patent/CN105229028B/zh active Active
- 2014-03-20 AU AU2014235933A patent/AU2014235933B2/en active Active
- 2014-03-20 DK DK17206987.4T patent/DK3312195T3/da active
- 2014-03-20 TW TW103110468A patent/TWI629995B/zh active
- 2014-03-20 ES ES17206987T patent/ES2763869T3/es active Active
- 2014-03-20 KR KR1020157028130A patent/KR102257138B1/ko active IP Right Grant
- 2014-03-20 RS RS20181438A patent/RS58188B2/sr unknown
- 2014-03-20 DK DK14717386.8T patent/DK2976359T4/da active
- 2014-03-20 CA CA2907422A patent/CA2907422C/en active Active
- 2014-03-20 PT PT14717386T patent/PT2976359T/pt unknown
- 2014-03-20 EP EP19194235.8A patent/EP3640260A1/en active Pending
- 2014-03-20 HR HRP20181939TT patent/HRP20181939T4/hr unknown
- 2014-03-20 HU HUE17206987A patent/HUE046702T2/hu unknown
-
2015
- 2015-08-25 PH PH12015501864A patent/PH12015501864B1/en unknown
- 2015-09-10 IL IL241461A patent/IL241461B/en unknown
- 2015-09-17 CL CL2015002801A patent/CL2015002801A1/es unknown
- 2015-09-18 MX MX2019009122A patent/MX2019009122A/es unknown
-
2016
- 2016-02-11 HK HK18112865.7A patent/HK1253717A1/zh unknown
- 2016-02-11 HK HK16101478.1A patent/HK1213576A1/zh unknown
-
2017
- 2017-02-08 US US15/427,920 patent/US10377819B2/en active Active
-
2019
- 2019-02-06 PH PH12019500261A patent/PH12019500261B1/en unknown
- 2019-02-12 JP JP2019022397A patent/JP6677837B2/ja active Active
- 2019-07-01 US US16/459,023 patent/US11230595B2/en active Active
- 2019-12-17 HR HRP20192277TT patent/HRP20192277T1/hr unknown
-
2020
- 2020-03-12 JP JP2020042524A patent/JP7016113B2/ja active Active
-
2021
- 2021-11-08 IL IL287915A patent/IL287915A/en unknown
- 2021-12-09 US US17/547,069 patent/US20220195025A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2983787T3 (da) | Fremgangsmåde til behandling af posttraumatisk stresssygdom | |
| DK2976359T4 (da) | Fremgangsmåder til behandling af osteogenesis imperfecta | |
| DK3076967T3 (da) | Fremgangsmåder til behandling af residuelle symptomer på skizofreni | |
| DK3035926T3 (da) | Forbindelser og fremgangsmåder til behandling af en epilepsilidelse | |
| DK3033086T3 (da) | Kombinationsterapi til behandling af cancer | |
| DK2968208T3 (da) | Behandling af kataplexi | |
| DK3125875T3 (da) | Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande | |
| DK3851537T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3043816T3 (da) | Anti-b7-h1-antistoffer til behandling af tumorer | |
| DK2964315T3 (da) | System til behandling af neuromotorisk dysfunktion | |
| DK3329884T3 (da) | Implanterbar indretning til behandling af glaukom | |
| DK3811943T3 (da) | Forbindelse til anvendelse til behandling af øjenlidelser | |
| DK3076976T3 (da) | Fremgangsmåder til behandling af cancer | |
| DK3054976T3 (da) | Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
| DK3007695T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
| DK2981255T3 (da) | Terapeutiske anvendelser af empagliflozin | |
| DK3021838T3 (da) | Behandling af fedme | |
| DK3062811T3 (da) | Angiopoietin-baserede interventioner til behandling af cerebral malaria | |
| DK3524255T3 (da) | Sammensætning til behandling af acne | |
| DK3007726T3 (da) | Fremgangsmåder til behandling af en tauopati | |
| DK3010895T3 (da) | Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner | |
| DK2994157T3 (da) | Tafa4-forbindelser og anvendelser deraf til behandling af smerte | |
| DK2906219T3 (da) | Orvepitant til behandling af kronisk pruritus |